



PRESS RELEASE – July 29, 2026 - 1:00 pm - Montpellier, France - Euronext: MEDCL

## UZEDY®: Record Q2 Net Sales of \$77M, Up 43% YoY; Teva Raises 2026 Outlook

Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record \$77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to \$270 million–\$290 million, from \$250 million–\$280 million previously.

According to Teva, based on IQVIA<sup>1</sup> data, UZEDY® continues to be the fastest-growing long-acting injectable treatment for schizophrenia in the U.S. U.S. prescriptions, normalized into months of therapy, increased 63% year-on-year, driven by increased volume per prescriber and continued expansion of the prescriber base, with more than 800 new prescribers added per month.

Medincell receives mid- to high-single-digit royalties on UZEDY® net sales and is eligible for up to \$105 million in commercial milestone payments, subject to the achievement of annual sales thresholds.

UZEDY® is a subcutaneous risperidone LAI (Long-Acting Injectable) approved in the U.S. for schizophrenia (one- and two-month dosing) and Bipolar I Disorder (one-month dosing).

### Olanzapine LAI

FDA action on Teva's once-monthly olanzapine LAI is anticipated in Q4 2026. Teva is preparing for launch, pending regulatory approval.

In Europe, the Marketing Authorization Application was accepted in Q2 2026.

**Teva Q2'26 results press release:** <https://ir.tevapharm.com/news-and-events/press-releases/default.aspx>

**Teva Q2'26 earnings conference call today at 8:00am ET:** <https://events.q4inc.com/attendee/303169536>

### About Medincell

Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.

These treatments combine active pharmaceutical ingredients with our proprietary BEPO® / BEPO® Star technologies, which enables controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot.

Risperidone LAI was the first treatment based on BEPO® technology to receive FDA approval, initially for schizophrenia in April 2023 (one- and two-month dosing), and subsequently for Bipolar I Disorder in October 2025 (one-month dosing). It is marketed in the United States by Teva under the brand name UZEDY®.

A New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment for schizophrenia in adults was submitted to the U.S. FDA in December 2025 by Medincell's partner, Teva. U.S. FDA accepted Teva's New NDA for Olanzapine LAI on February 20, 2026. A European Marketing Authorization Application (MAA) was also accepted by EMA in May 2026.

Medincell's investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.

Headquartered in Montpellier, France, Medincell employs over 150 people representing more than 27 nationalities.

**medincell.com**

UZEDY® is a trademark of Teva Pharmaceuticals. Medincell's BEPO® technology is licensed to Teva as SteadyTeq™, a trademark of Teva Pharmaceuticals.

<sup>1</sup> IQVIA is a global healthcare company specializing in data analytics, clinical research, and technology solutions for the pharmaceutical industry and healthcare stakeholders.

## Contact

---

### David Heuzé

Head of Corporate and Financial Communications, and ESG  
david.heuze@medincell.com / +33 (0)6 83 25 21 86

### Grace Kim

Chief Strategy Officer, U.S. Finance  
grace.kim@medincell.com / +1 (646) 991-4023

### Nicolas Mérieux / Gaëlle Fromaigeat

Media Relations  
Medincell@newcap.eu / +33 (0)1 44 71 94 94

### Louis-Victor Delouvrier / Alban Dufumier

Investor Relations France  
Medincell@newcap.eu / +33 (0)1 44 71 94 94

This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's universal registration document, filed with the AMF on July 29, 2025, under number D. 25-0580 (the "Universal Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 30 *et seq.* 26 of the Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions.